We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Life Science REIT (LABS) ORD GBP0.01

Sell:33.00p Buy:33.40p 0 Change: 1.00p (2.94%)
Market closed Prices as at close on 22 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:33.00p
Buy:33.40p
Change: 1.00p (2.94%)
Market closed Prices as at close on 22 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:33.00p
Buy:33.40p
Change: 1.00p (2.94%)
Market closed Prices as at close on 22 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Objective

The Company will seek to achieve its investment objective by investing in a diversified portfolio of properties across the UK which are typically leased or intended to be leased to tenants operating in, or providing a benefit to, the life science sector. Life science is the branch of sciences concerned with the study of living organisms. This encompasses the study of the breadth of life processes, and the structure and behaviour of living things. Companies operating in the life science sector include, but are not limited to, those involved in the innovation, development and/or production of assets directly or indirectly for human health purposes.
Security Weight
Investment Property 134.73%

Top 10 sectors currently unavailable.

Top 10 countries currently unavailable.

Fee Structure

The Investment Adviser will be paid an annual advisory fee of 1.1% of NAV up to GBP 500 m 0.9% of NAV in excess of GBP 500m and up to GBP1b and 0.75% of NAV in excess of GBP1B exclusive of VAT. The contract may be terminated on giving 24 months notice from the fourth anniversary of Admission.

Dividend Policy

The Board intends to adopt a progressive dividend policy, with dividends paid semi-annually.

ASSET SPLIT

Total number of holdings: 4.

Trust Manager

Not currently available for this investment trust.

Manager Bio

Not currently available for this investment trust.

Board Of Directors

Claire BoyleChairman, Richard Howell, Sally Forsyth, Michael Taylor

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.